Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00034255
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
2002-04-24
Brief Title:
Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients
Sponsor:
GMP Endotherapeutics
Organization:
GMP Endotherapeutics
Study Overview
Official Title:
Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients
Status:
COMPLETED
Status Verified Date:
2003-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of intramuscular INGAP Peptide given for the first time in humans as a potential treatment for diabetes
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None